Product Reports Resources Pricing Login Book a demo

Five Prime Therapeutics

Biotech & Life Sciences · South San Francisco, United States · Founded 2001 · IPO 2013

Innovative Protein Therapeutics

Valuation $1.90B
Revenue $12M
Power Law Unicorn$1–10B valuation tier

Talent graph

Five Prime Therapeutics's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia 4 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on Five Prime Therapeutics's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series B+ 7 investors entered at this stage
HealthCap
Wellcome Trust
Kleiner Perkins
Versant Ventures
Advanced Technology Ventures
Domain Associates
Diamond Capital Company

Five Prime Therapeutics mafia

Startups founded by Five Prime Therapeutics alumni

Former Five Prime Therapeutics employees who went on to start their own companies. Sorted by Dealroom signal score.

RayzeBioEst. 2020
Deborah Charych, Ph.D.United States
Signal score93
NurixEst. 2012
Arthur WeissUnited States
Signal score73
Cell Design LabsEst. 2015
BABrian AtwoodUnited States
Signal score53
alive.cnEst. 2011
Brian WongChina
Signal score52

Book a demo to explore the full alumni network →

Global footprint

Where Five Prime Therapeutics has talent and traffic

Workforce by country
🇺🇸 United States · South San Francisco HQ
Book a demo for the full country breakdown

Patent intelligence

$123M patent portfolio · 51 active families

Estimated portfolio value
$123M
6.5% of market cap · 2.6× smaller than top peer MorphoSys ($321M)
51 active patent families
Where Five Prime Therapeutics innovates Anti antibodyAntibodyAntiendomysial antibodiesCancerCancer research

Where Five Prime Therapeutics concentrates vs peers

Each axis is a top-10 topic across Five Prime Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Five Prime Therapeutics

An AI-synthesized read of the highest-engagement posts about Five Prime Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Five Prime Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles